000180700 001__ 180700
000180700 005__ 20240229145629.0
000180700 0247_ $$2doi$$a10.1158/1055-9965.EPI-21-1033
000180700 0247_ $$2pmid$$apmid:35839461
000180700 0247_ $$2ISSN$$a1055-9965
000180700 0247_ $$2ISSN$$a1538-7755
000180700 0247_ $$2altmetric$$aaltmetric:132607280
000180700 037__ $$aDKFZ-2022-01496
000180700 041__ $$aEnglish
000180700 082__ $$a610
000180700 1001_ $$00000-0002-1932-7463$$aSmith-Byrne, Karl$$b0
000180700 245__ $$aCirculating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Pre-Diagnostic Blood Measurements.
000180700 260__ $$aPhiladelphia, Pa.$$bAACR$$c2022
000180700 3367_ $$2DRIVER$$aarticle
000180700 3367_ $$2DataCite$$aOutput Types/Journal article
000180700 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1665143237_4150
000180700 3367_ $$2BibTeX$$aARTICLE
000180700 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180700 3367_ $$00$$2EndNote$$aJournal Article
000180700 500__ $$a 2022 Oct 4;31(10):1966-1974
000180700 520__ $$aTobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies.We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide-association studies (GWAS) of blood metabolite levels (n =7,824) and lung cancer risk (n=29,266 cases / 56,450 controls). A nested case control study (656 cases and 1,309 matched controls) was subsequently performed using pre-diagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS).An MR-based scan of 207 circulating metabolites for lung cancer risk identified that blood isovalerylcarnitine (IVC) was associated with a decreased odds of lung cancer after accounting for multiple testing (Log10-OR = 0.43, 95% CI: 0.29-0.63). Molar measurement of IVC in pre-diagnostic blood found similar results (Log10-OR = 0.39, 95% CI: 0.21-0.72). Results were consistent across lung cancer sub-types.Independent lines of evidence support an inverse association of elevated circulating IVC with lung cancer risk through a novel methodological approach that integrates genetic and traditional epidemiology to efficiently identify novel cancer biomarkers.Our results find compelling evidence in favor of a protective role for a circulating metabolite, IVC, in lung cancer aetiology. From the treatment of a Mendelian disease, isovaleric acidemia, we know that circulating IVC is modifiable through a restricted protein diet or glycine and L-carnatine supplementation. IVC may represent a modifiable and inversely associated biomarker for lung cancer.
000180700 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180700 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180700 7001_ $$00000-0002-9633-7796$$aCerani, Agustin$$b1
000180700 7001_ $$00000-0002-9652-2430$$aGuida, Florence$$b2
000180700 7001_ $$00000-0003-4963-0815$$aZhou, Sirui$$b3
000180700 7001_ $$00000-0001-9900-5677$$aAgudo, Antonio$$b4
000180700 7001_ $$00000-0002-1275-1827$$aAleksandrova, Krasimira$$b5
000180700 7001_ $$00000-0001-6750-1270$$aBarricarte, Aurelio$$b6
000180700 7001_ $$00000-0002-9972-9779$$aRodríguez-Barranco, Miguel$$b7
000180700 7001_ $$00000-0003-2394-6512$$aBorchers, Christoph H$$b8
000180700 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b9
000180700 7001_ $$00000-0002-9477-8782$$aHan, Jun$$b10
000180700 7001_ $$00000-0002-8540-7023$$aAmos, Christopher I$$b11
000180700 7001_ $$00000-0002-4486-7496$$aHung, Rayjean J$$b12
000180700 7001_ $$00000-0003-4289-2097$$aGrankvist, Kjell$$b13
000180700 7001_ $$00000-0001-6805-3094$$aNøst, Therese H$$b14
000180700 7001_ $$00000-0002-3777-4953$$aImaz, Liher$$b15
000180700 7001_ $$00000-0001-9242-3040$$aChirlaque-López, María Dolores$$b16
000180700 7001_ $$00000-0003-4182-8923$$aJohansson, Mikael$$b17
000180700 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b18$$udkfz
000180700 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b19
000180700 7001_ $$00000-0002-7992-7719$$aMartin, Richard M$$b20
000180700 7001_ $$00000-0002-1787-3874$$aMcKay, James D$$b21
000180700 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b22
000180700 7001_ $$00000-0001-6041-6866$$aRobbins, Hilary A$$b23
000180700 7001_ $$00000-0002-4062-872X$$aSandanger, Torkjel M$$b24
000180700 7001_ $$00000-0001-8249-8188$$aSchibli, David$$b25
000180700 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b26
000180700 7001_ $$00000-0002-9571-0763$$aTravis, Ruth C$$b27
000180700 7001_ $$00000-0001-8935-4566$$aVineis, Paolo$$b28
000180700 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b29
000180700 7001_ $$00000-0002-0518-8714$$aBrennan, Paul$$b30
000180700 7001_ $$00000-0002-3116-5081$$aJohansson, Mattias$$b31
000180700 7001_ $$00000-0002-3746-9086$$aRichards, J Brent$$b32
000180700 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-21-1033$$gp. EPI-21-1033$$n10$$p1966-1974$$tCancer epidemiology, biomarkers & prevention$$v31$$x1055-9965$$y2022
000180700 909CO $$ooai:inrepo02.dkfz.de:180700$$pVDB
000180700 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000180700 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000180700 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180700 9141_ $$y2022
000180700 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000180700 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000180700 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000180700 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2021$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000180700 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-10
000180700 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000180700 980__ $$ajournal
000180700 980__ $$aVDB
000180700 980__ $$aI:(DE-He78)C020-20160331
000180700 980__ $$aUNRESTRICTED